GlassScriptPhysician profile
Mckenzie Knapick
NPI 1366194920
$3,506.56
in general payments reported to CMS, 2019-2025
28 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,544 · 2023: $1,148 · 2024: $815.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,962.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,962.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $804.89 | 2022-2024 | |
| Novo Nordisk INC | $653.03 | 2022-2024 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $260.91 | 2022-2024 | Otezla, Repatha, Evenity |
| Lilly USA, LLC | $238.83 | 2022-2024 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $216.40 | 2022-2024 | Airsupra, Breztri, Fasenra |
| Takeda Pharmaceuticals U.S.A., INC. | $123.51 | 2022-2023 | Trintellix |
| Antares Pharma, INC. | $116.45 | 2022-2023 | Nocdurna, Tlando, Xyosted |
| Otsuka America Pharmaceutical, INC. | $115.29 | 2022-2024 | Rexulti, Abilify Maintena |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $114.73 | 2022-2023 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $109.66 | 2022-2024 | Jardiance, Tradjenta, Synjardy |
| Novartis Pharmaceuticals Corporation | $90.08 | 2023-2024 | |
| Glaxosmithkline, LLC. | $78.70 | 2022-2024 | Arexvy |
| Bayer Healthcare Pharmaceuticals INC. | $73.59 | 2022-2024 | |
| Merck Sharp & Dohme LLC | $60.26 | 2022-2023 | Vaxelis, Pneumovax 23, Vaxneuvance |
| Astellas Pharma US INC | $57.41 | 2023-2024 | Veozah, Myrbetriq |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $55.46 | 2022 | |
| Nestle Healthcare Nutrition INC. | $44.57 | 2022-2023 | |
| Idorsia Pharmaceuticals US INC | $41.99 | 2022-2023 | Quviviq |
| Paratek Pharmaceuticals, INC. | $41.60 | 2022 | |
| Horizon Therapeutics Plc | $41.37 | 2022 | |
| Amarin Pharma, INC. | $37.79 | 2022 | |
| Pfizer INC. | $36.87 | 2022-2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $16.98 | 2022 | |
| Pulmonx Corporation | $16.65 | 2022 | |
| Mckesson Medical-Surgical, INC. | $15.83 | 2023 | |
| Organon LLC | $15.59 | 2023 | Nexplanon |
| Bausch Health US, LLC | $14.11 | 2022 | |
| Esperion Therapeutics, INC. | $14.01 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mckenzie Knapick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.